Immunome (NASDAQ:IMNM) Reaches New 12-Month Low – What’s Next?

Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price hit a new 52-week low on Friday. The company traded as low as $16.38 and last traded at $16.3930, with a volume of 561 shares changing hands. The stock had previously closed at $16.61.

Analysts Set New Price Targets

IMNM has been the topic of a number of recent research reports. Stifel Nicolaus cut their target price on shares of Immunome from $24.00 to $23.00 and set a “hold” rating on the stock in a report on Tuesday, November 10th. Alliance Global Partners assumed coverage on Immunome in a report on Monday, September 21st. They issued a “buy” rating and a $32.00 price target on the stock. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Immunome in a research report on Tuesday, October 27th. Finally, William Blair started coverage on Immunome in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average price target of $33.85.

View Our Latest Stock Analysis on IMNM

Immunome Price Performance

The stock has a fifty day moving average price of $19.74 and a two-hundred day moving average price of $22.01. The company has a market cap of $1.85 billion, a P/E ratio of -5.94 and a beta of 2.68.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, analysts forecast that Immunome, Inc. will post -2.64 earnings per share for the current year.

Insider Transactions at Immunome

In other Immunome news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. The trade was a 16.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.21% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Allworth Financial LP acquired a new stake in Immunome in the second quarter worth about $25,000. Integrated Wealth Concepts LLC acquired a new position in Immunome during the 2nd quarter valued at about $27,000. KBC Group NV acquired a new position in Immunome during the 1st quarter valued at about $60,000. GK Wealth Management LLC bought a new stake in shares of Immunome during the 3rd quarter worth about $71,000. Finally, Sterling Capital Management LLC raised its position in shares of Immunome by 840.0% during the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after buying an additional 3,108 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

(Get Free Report)

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

See Also

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.